Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III CHRONOS-3 Study for Relapsed Indolent Non-Hodgkin's Lymphoma
Shots:
- The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment
- The P-II study met its 1EP of prolonged PFS- safety is consistent with previously published data on the individual components of the combination- no new safety signals were identified
- Aliqopa is a PI3K inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells and is an approved treatment for patients with relapsed FL prior treated with two systemic therapies
Ref: Businesswire Image: Business Insider
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com